Overview

Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices

Status:
Unknown status

Trial end date:
2017-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess whether the add of Rifaximin in patients with liver cirrhosis and esophageal varices treated with a standard therapy with beta blockers, leads to a significant reduction of portal hypertension.

Phase:

Phase 3

Details

Lead Sponsor:

University of Padova
University of Padua

Treatments:

Rifamycins
Rifaximin